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Abstract 
Streptococcus pyogenes (group A Streptococcus [GAS]) causes ~700 million human infections/year, 
resulting in >500,000 deaths. There is no commercial GAS vaccine available. The GAS surface protein 
arginine deiminase (ADI) protects mice against a lethal challenge. ADI is an enzyme that converts 
arginine to citrulline and ammonia. Administration of a GAS vaccine preparation containing wild-type ADI, 
a protein with inherent enzymatic activity, may present a safety risk. In an approach intended to maximize 
the vaccine safety of GAS ADI, X-ray crystallography and structural immunogenic epitope mapping were 
used to inform vaccine design. This study aimed to knock out ADI enzyme activity without disrupting the 
three-dimensional structure or the recognition of immunogenic epitopes. We determined the crystal 
structure of ADI at 2.5 Å resolution and used it to select a number of amino acid residues for mutagenesis 
to alanine (D166, E220, H275, D277, and C401). Each mutant protein displayed abrogated activity, and 
three of the mutant proteins (those with the D166A, H275A, and D277A mutations) possessed a 
secondary structure and oligomerization state equivalent to those of the wild type, produced high-titer 
antisera, and avoided disruption of B-cell epitopes of ADI. In addition, antisera raised against the D166A 
and D277A mutant proteins bound to the GAS cell surface. The inactivated D166A and D277A mutant 
ADIs are ideal for inclusion in a GAS vaccine preparation. There is no human ortholog of ADI, and we 
confirm that despite limited structural similarity in the active-site region to human peptidyl ADI 4 (PAD4), 
ADI does not functionally mimic PAD4 and antiserum raised against GAS ADI does not recognize human 
PAD4. 
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Structure-Informed Design of an Enzymatically Inactive Vaccine
Component for Group A Streptococcus
Anna Henningham,a* Daniel J. Ericsson,a Karla Langer,a Lachlan W. Casey,a Blagojce Jovcevski,b G. Singh Chhatwal,c
J. Andrew Aquilina,b Michael R. Batzloff,d Bostjan Kobe,a,e Mark J. Walkera
School of Chemistry and Molecular Biosciences, Australian Infectious Diseases Research Centre, University of Queensland, St. Lucia, Qld., Australiaa; Illawarra Health and
Medical Research Institute and School of Biological Sciences, University of Wollongong, Wollongong, NSW, Australiab; Department of Medical Microbiology, Helmholtz
Centre for Infection Research, Braunschweig, Germanyc; Institute for Glycomics, Griffith University, Southport, Qld., Australiad; Division of Chemistry and Structural Biology,
Institute for Molecular Bioscience, University of Queensland, St. Lucia, Qld., Australiae
* Present address: Department of Pediatrics, University of California San Diego, La Jolla, California, USA.
ABSTRACT Streptococcus pyogenes (group A Streptococcus [GAS]) causes ~700 million human infections/year, resulting in
>500,000 deaths. There is no commercial GAS vaccine available. The GAS surface protein arginine deiminase (ADI) protects
mice against a lethal challenge. ADI is an enzyme that converts arginine to citrulline and ammonia. Administration of a GAS vac-
cine preparation containing wild-type ADI, a protein with inherent enzymatic activity, may present a safety risk. In an approach
intended to maximize the vaccine safety of GAS ADI, X-ray crystallography and structural immunogenic epitope mapping were
used to inform vaccine design. This study aimed to knock out ADI enzyme activity without disrupting the three-dimensional
structure or the recognition of immunogenic epitopes. We determined the crystal structure of ADI at 2.5 Å resolution and used it
to select a number of amino acid residues for mutagenesis to alanine (D166, E220, H275, D277, and C401). Each mutant protein
displayed abrogated activity, and three of the mutant proteins (those with the D166A, H275A, and D277A mutations) possessed
a secondary structure and oligomerization state equivalent to those of the wild type, produced high-titer antisera, and avoided
disruption of B-cell epitopes of ADI. In addition, antisera raised against the D166A and D277A mutant proteins bound to the
GAS cell surface. The inactivated D166A and D277A mutant ADIs are ideal for inclusion in a GAS vaccine preparation. There is
no human ortholog of ADI, and we confirm that despite limited structural similarity in the active-site region to human peptidyl
ADI 4 (PAD4), ADI does not functionally mimic PAD4 and antiserum raised against GAS ADI does not recognize human PAD4.
IMPORTANCE We present an example of structural biology informing human vaccine design. We previously showed that the ad-
ministration of the enzyme arginine deiminase (ADI) to mice protected the mice against infection with multiple GAS serotypes.
In this study, we determined the structure of GAS ADI and used this information to improve the vaccine safety of GAS ADI. Cat-
alytically inactive mutant forms of ADI retained structure, recognition by antisera, and immunogenic epitopes, rendering them
ideal for inclusion in GAS vaccine preparations. This example of structural biology informing vaccine design may underpin the
formulation of a safe and efficacious GAS vaccine.
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Group A Streptococcus (GAS) is an exclusively human pathogenthat colonizes primarily the upper respiratory tract and the
skin. GAS is responsible for common mild infections such as phar-
yngitis and impetigo and, at a lower frequency, severe invasive
conditions, including necrotizing fasciitis and streptococcal toxic
shock-like syndrome. Reoccurring GAS infection can elicit non-
suppurative sequelae, including acute rheumatic fever, rheumatic
heart disease, and acute poststreptococcal glomerulonephritis (1–
3). There is no safe and efficacious commercial GAS vaccine avail-
able. GAS vaccinology has focused primarily on the major viru-
lence factor, the surface-exposed M protein. GAS serotypes are
designated on the basis of their patterns of M protein expression.
M protein has been widely reported to protect against GAS infec-
tion (4), and two vaccine formulations based on a subset of M
types have reached human clinical trials (5, 6). Despite this prog-
ress, there are shortcomings in the targeting of specific M proteins,
including the occurrence of many unique serotypes (there are
200 known circulating types of GAS M protein [7]), antigenic
variation within the same serotype, differences in the geographical
distribution of serotypes (8, 9), and the production of antibodies
cross-reactive with human tissue, which can lead to host autoim-
mune disease (3). In addition to M protein, a number of other
GAS surface-localized and secreted antigens have been tested as
vaccine candidates in mouse infection models, including fibronectin-
binding protein A, R28 protein, protein F1, serum opacity factor
(SOF), streptococcal protective antigen, Streptococcus pyogenes cell
envelope proteinase (SpyCEP), C5a peptidase, streptococcal hemo-
protein receptor, streptococcal pyrogenic exotoxin B (SpeB), strep-
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tococcal secreted esterase, streptolysin O (SLO), fibronectin-binding
protein 54, streptococcal immunoglobulin-binding protein 35, and
trigger factor (4). While all of these antigens show promise, none
have progressed past animal-based trials.
We previously characterized arginine deiminase (ADI) as a
GAS vaccine candidate. ADI is localized on the cell surface and
produces opsonic antibodies capable of protecting mice against
lethal challenges with homologous and heterologous GAS isolates
(10). ADI is one of three enzymes in the ADI pathway and con-
verts arginine to citrulline with the concomitant production of
ammonia. In GAS, the enzymatic activity of ADI protects cells
from low-pH environments (11, 12). Administration of a GAS
vaccine preparation containing wild-type ADI, a protein with in-
herent enzymatic activity, may result in undesirable safety con-
cerns. Some of the other previously reported GAS vaccine antigens
possess enzyme activity, including C5a peptidase (13), SLO (14,
15), SpyCEP (15, 16), SOF (17), and SpeB (18). These antigens
have been successfully deactivated via truncation or site-directed
mutagenesis as a means of improving their safety profile.
Here we used X-ray crystallography and structural immuno-
genic epitope mapping to inform vaccine safety and design. We
determined the crystal structure of GAS ADI at 2.48 Å resolution.
A number of individual residues were targeted for site-directed
mutagenesis on the basis of their positions in the GAS structure
and following the comparison of GAS ADI to other ADI structures
in which the active site was known, including those of Mycoplasma
arginini (19) and Pseudomonas aeruginosa (20–22). We identify
two site-directed mutant forms of ADI, the D166A and D277A
mutant proteins, with unaltered antigenic characteristics and an
ideal safety profile, as novel GAS vaccine components.
RESULTS
GAS ADI structure and active site. The structure of GAS ADI was
determined at 2.48 Å resolution by molecular replacement by us-
ing the structure of M. arginini ADI (19) as the search model (see
Table S1 in the supplemental material). The asymmetric unit con-
tains 8 molecules, the C atoms of which superpose with root
mean square distances (RMSDs) ranging from 0.19 to 0.53 Å. As
with other available ADI structures, GAS ADI consists of two do-
mains, one consisting of five  motifs repeated around a
pseudo-5-fold axis that contains the active site. The other is an
orthogonal four-helix bundle (Fig. 1A and C). GAS ADI has an
analogous structure in ADIs from other species. It superposes with
those of M. arginini and P. aeruginosa with RMSDs of 1.31 and
1.56 Å, respectively, with deviations in one loop close to the active
site (GAS ADI residues 268 to 274), one loop distal to the active
site (residues 338 to 341), and the largest differences found in the
four-helix bundle domain (residues 97 to 100 and 129 to 152). The
GAS ADI active-site residues (D166, E220, H275, D277, and C401;
Fig. 1B) superpose closely with those of M. arginini and P. aerugi-
nosa, and several molecules in the asymmetric unit even contain a
region of strong positive density in the active site, coinciding with
the citrulline moiety bound to the M. arginini structure (19). This
indicates that a molecule, possibly a bound substrate molecule,
has been copurified with the protein, but the resulting electron
density maps are not distinct enough to model this with certainty.
Strategy for ADI enzyme mutagenesis. GAS ADI was found to
share 41.3 and 36.0% sequence identity with the ADIs of M. argi-
nini and P. aeruginosa, respectively. As the ADI active site has been
well characterized in both of these species (19–22), residues for
site-directed mutagenesis were selected following comparison of
the GAS ADI structure to these structures. Residues D166, E220,
H274, D277, and C401, all buried in the active-site pocket
(Fig. 1B), were individually converted to alanine in recombinant
GAS ADI, as these residues were predicted to be part of the active
site or to be involved in catalysis.
Enzyme activities of wild-type and mutant ADIs. We per-
formed an endpoint colorimetric assay for the determination of
citrulline to ascertain if the mutant ADIs had lost enzymatic ac-
tivity. The conversion of arginine to citrulline was measured at
540 nm following the reaction of citrulline with 2,3-butanedione
monoxime at a high temperature (95°C) in the presence of the
reducing agent thiosemicarbazide, strong acids (H2SO4 and
H3PO4), and catalytic quantities of Fe3. The concentration of
citrulline produced by 1 mg of wild-type ADI in 1 h was 338 mM
(Fig. 1D). This concentration was significantly greater (P  0.05)
than that produced by any of the mutant ADIs, in all of which
enzyme activity was abolished (1.3 mM; Fig. 1D).
Structural characterization of mutant ADIs. To confirm that
the mutations in ADI did not alter protein structure or oligomer-
ization, intrinsic tryptophan fluorescence, circular-dichroism
(CD), and electrospray ionization (ESI)-mass spectrometry (MS)
measurements were undertaken. ESI-MS was used to determine
the mass-to-charge ratio of each mutant protein, which can be
used to indicate a monomeric state(s). The D166A, E220A,
H275A, and D277A mutant ADIs maintained the wild-type sec-
ondary structure, as indicated by intrinsic tryptophan fluores-
cence (Fig. 1E) and CD spectra (Fig. 1F). However, the tryptophan
fluorescence and CD spectrum of the C401A mutant protein in-
dicated an alteration in secondary structure compared to that of
wild-type ADI (Fig. 1E and F). ESI-MS indicated that wild-type
ADI exists as a mixture of monomers and dimers (Fig. 1G). Like-
wise, the D166A, E220A, H275A, and D277A mutant proteins
exist as a mixture of monomeric and dimeric states (Fig. 1G). On
the other hand, the C401A mutant protein existed exclusively as a
tetramer (Fig. 1G). Size exclusion chromatography confirmed the
finding that the C401A mutant ADI was tetrameric (data not
shown). Small-angle X-ray scattering (SAXS) was used to further
characterize the C401A mutant protein. The data suggest that the
C401A mutant protein is a globular particle with a volume-
derived molecular mass of 197.4 kDa (see Fig. S1 in the supple-
mental material), suggesting that it forms a stable tetrameric spe-
cies in solution.
Immunogenicity of mutant ADIs. To assess whether the mu-
tant ADIs could stimulate a humoral response capable of recog-
nizing wild-type ADI, a murine immunization model was used.
Following subcutaneous immunization with complete Freund’s
adjuvant, each mutant ADI was observed to be immunogenic,
stimulating a strong serum IgG response capable of recognizing
wild-type ADI. When assessed by enzyme-linked immunosorbent
assay (ELISA), the serum raised against each mutant ADI bound a
quantity of immobilized wild-type ADI equivalent to that bound
by serum generated against wild-type ADI (Fig. 2A). The average
IgG titers (n  5) for the proteins were as follows: wild-type ADI,
1,638,400; D166A mutant ADI, 1,064,960; E220A mutant ADI,
696,320; H275A mutant ADI, 942,080; D277A mutant ADI,
1,310,720; C401A mutant ADI, 1,884,160.
Antisera raised against mutant ADIs bind the GAS cell sur-
face. To investigate the capacity of sera raised against mutant ADIs
to bind native ADI on the GAS cell surface, flow cytometry was
Henningham et al.
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used. Antiserum raised against the surface-bound M protein was
used as a positive control, while Tris-buffered saline (TBS; 0.14 M
NaCl, 2.7 mM KCl, 0.05 M Tris base, pH 7.0) sham serum was
used as a negative control. Preincubation of GAS with antisera
generated against the M1 protein (data not shown), or the wild-
type, D166A mutant, E220A mutant, D277A mutant, and C401A
mutant ADIs resulted in a significant shift in geometric mean
surface fluorescence in comparison to TBS sham serum (Fig. 2B to
D and F to G; P  0.05). Serum raised against H275A mutant ADI
also resulted in a shift, which was not statistically significant
(Fig. 2E; P  0.05).
Mapping of linear B-cell epitopes of ADI. To conduct a pre-
liminary characterization of the discrete B-cell epitopes within
ADI, an overlapping peptide array membrane containing 15-mer
peptides spanning the complete sequence of ADI was synthesized.
Each consecutive peptide was shifted by three residues toward the
C terminus of the protein. The membrane was probed with pooled
antisera (n  5) generated against wild-type ADI, stripped, and
FIG 1 Enzymatic and structural comparisons of wild-type and mutant ADIs. (A) Model of the GAS ADI crystal structure illustrating the pseudo-5-fold axis of
the catalytic domain in green, blue, pink, cyan, and red, respectively, with the helical orthogonal bundle in orange and the remaining structural elements in gray.
(B) ADI active-site residues targeted for site-directed mutagenesis. (C) Topology diagram of GAS ADI, colored as in panel A. (D) Colorimetric assay for the
determination of citrulline. Triplicate data from two independent replicate experiments are presented. Error bars indicate the standard deviations. Wild-type
ADI produced a significantly greater amount of citrulline than each mutant ADI, as determined by one-way ANOVA (P  0.05; indicated by an asterisk). (E)
Tryptophan emission fluorescence spectra of wild-type ADI and mutant proteins. Wild-type ADI and the D166A, E220A, H275A, and D277A mutant ADIs
exhibited nearly identical emission maxima (347 to 349 nm), whereas that of C401A mutant ADI was red shifted to 330 nm, which is indicative of significantly
altered tertiary and/or quaternary structure. (F) UV CD spectra (200 to 260 nm) comparing the secondary structures of mutant ADIs to that of wild-type ADI.
(G) ESI-MS spectra of wild-type and mutant ADIs. Wild-type ADI and the D166A, E220A, H275A, and D277A mutant ADIs exist as a monomer-dimer mixture,
while C401A exists exclusively in a tetrameric form.
Inactivation of ADI for Use as a GAS Vaccine Candidate
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subsequently probed with a pool of TBS sham serum (n  5).
Incubation of the peptide arrays with the TBS sham serum re-
sulted in no colorimetric reaction (Fig. 3B). In contrast, several
discrete peptide spots were detected on the peptide array following
probing with antiserum raised against wild-type ADI (Fig. 3A).
Reactive spots are indicated within magenta boxes in Fig. 3A.
Probing of the ADI peptide array with anti-wild-type ADI serum
resulted in the identification of 10 linear B-cell epitopes (Fig. 3A
[magenta outline] and H [highlighted]). Mapping of the immu-
nogenic epitopes onto the structure of GAS ADI (Fig. 3I) indicated
that the majority of the active-site residues (in bold in Fig. 3H)
were not found in linear B-cell epitopes.
Effect of site-directed mutagenesis on the immunogenic
B-cell epitopes of ADI. Following stripping, the membrane was
further probed with pools of antisera (n  5) raised against each
individual mutant ADI. For sera raised against the D166A
(Fig. 3C), E220A (Fig. 3D), and H275A (Fig. 3E) mutant proteins,
the same pattern of linear epitopes was recognized as when anti-
wild-type ADI serum was used to probe the array (Fig. 3A). Serum
generated against the D277A mutant protein recognized the same
immunogenic epitopes as wild-type ADI serum, with an addi-
tional string of three peptides (Fig. 3F; peptides 48 to 50). For the
sera raised against the D166A, H275A, D277A, and C401A mutant
proteins, the peptide spots containing the respective mutations
(Fig. 3) did not result in colorimetric development. The serum
raised against the E220A mutant protein, however, did react with
the peptide spots containing the E220 residue (Fig. 3D). Colori-
metric development following probing of the peptide array with
anti-C401A mutant ADI serum (Fig. 3G) resulted in substantially
fewer developed spots than probing with anti-wild-type ADI se-
rum (Fig. 3A). The anti-C401A mutant ADI serum reacted with
only five of the immunogenic epitopes recognized by anti-wild-
type ADI serum.
Comparison of GAS ADI to human PAD4. Peptidyl ADI 4
(PAD4) is known to convert arginine residues to citrulline in his-
tones (23) and chemokines (24) within the host. To determine if
ADI could be molecularly mimicking the function of human
PAD4, we first compared the structure of GAS ADI to that of
PAD4 (Protein Data Bank accession no. 2DW5) (25). These su-
perpose with an RMSD of 2.8 Å over 216 residues, with the ma-
jority of the deviation coming from the larger -helical elements
present in PAD4. In contrast, the active-site residues of the two
structures overlap with an RMSD of 1.0 Å (Fig. 4A). Western
blotting indicated that recombinant human PAD4 successfully
citrullinated host targets in vitro (Fig. 4B). However, recombinant
wild-type ADI did not citrullinate host targets of PAD4 in vitro,
including histone H3, LL-37, or interleukin-8 (IL-8) (Fig. 4B).
Antiserum raised against wild-type ADI did not recognize human
PAD4 in Western blot assays (Fig. 4C). Additionally, incubation
of anti-wild-type ADI serum with immobilized PAD4 in an ELISA
did not result in a measurable response (data not shown).
DISCUSSION
Structural biology is being increasingly used for the rational de-
sign and optimization of vaccine antigens. Knowledge of the
structure of a given antigen may allow researchers to design sub-
units, peptides, or other vaccine constituents based on a particular
region. Structural information can also facilitate inactivation or
detoxification of antigens possessing enzyme activity or toxic ef-
fects. Other recent studies using structural biology for the optimi-
FIG 2 Capacity of antisera raised against mutant ADIs to recognize recom-
binant and native wild-type ADIs. BALB/c mice (n  5) were immunized via
the subcutaneous route with each individual ADI protein. Negative control
mice were sham immunized with TBS and adjuvant only. Mice were adminis-
tered 10 g of protein on days 0, 21, and 28. Serum was collected on day 42. (A)
Serum-specific IgG antibody titers determined by ELISA by using wild-type
(WT) ADI to coat the plate. TBS sham serum did not produce measurable IgG
titers against ADI. The absorbance cutoff for IgG titer determination was 0.2.
Error bars represent the standard error of the mean. (B to G) Quantification of
native ADI on the surface of GAS M1T1 isolate 5448 by flow cytometry. The
histograms obtained for sera immunized with ADI proteins are indicated with
a solid line; shading indicates the histogram for TBS sham serum. Panels: B,
wild-type ADI; C, D166A mutant ADI; D, E220A mutant ADI; E, H275A
mutant ADI; F, D277A mutant ADI; G, C401A mutant ADI. Incubation of
GAS with sera raised against wild-type ADI and the D166A, E220A, D277A,
and C401A mutant ADIs resulted in a significant shift in geometric mean
surface fluorescence (P  0.05; indicated by an asterisk) in comparison with
that obtained with TBS sham serum. Triplicate data from two independent
replicate experiments were obtained, and representative histograms are pre-
sented.
Henningham et al.
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zation of GAS vaccine candidates include SLO (14) and JJo (26), a
chimeric protein based on the J14 epitope of the M1 protein. Re-
searchers have also turned to a structural approach for the opti-
mization of vaccine antigens effective against other streptococcal
species, including group B Streptococcus (27) and meningococcus
(28). The present study paired a structural biology approach with
linear epitope mapping to facilitate the optimization of the GAS
vaccine antigen ADI.
Previous studies undertaking site-directed mutagenesis of re-
combinant ADIs from M. hominis (29) and P. aeruginosa (22)
identified a number of mutations that led to a complete loss of
enzyme activity. In this study, we identified residues in GAS ADI
(D166, E220, H275, D277, and C401) whose mutation to alanine
resulted in a complete abrogation of enzymatic activity. On the
basis of these results and the X-ray crystal structure of ADI, we
propose that residues Glu220, His275, and Cys401 form the cata-
lytic triad of GAS ADI.
The crystal structure of ADI indicated that the residues of the
active site are shielded within a pocket. This observation suggests
that the active site may not be readily accessible to antisera recog-
nizing conformational epitopes. Nonetheless, antibodies recog-
nizing linear epitopes may bind to active-site residues. To ensure
that mutation of active-site residues did not alter the recognition
and binding profile of anti-ADI sera, we immunized mice with the
FIG 3 Determination of linear B-cell epitopes and immunogenic peptide mapping of wild-type ADI. Spots 1 to 133 are 15-residue-long peptides encompassing
the ADI sequence immobilized on cellulose membrane. Each peptide is shifted by 3 amino acids toward the C terminus. (A to G) Membranes probed with pooled
serum from BALB/c mice (n  5) subcutaneously immunized as follows: A, wild-type ADI; B, TBS (sham); C, D166A mutant ADI; D, E220A mutant ADI; E,
H275A mutant ADI; F, D277A mutant ADI; G, C401A mutant ADI. (H) Linear B-cell epitopes are highlighted in rainbow colors, starting with blue at the N
terminus and ending with red at the C terminus. Individual residues targeted by site-directed mutagenesis are in bold with underlining. (I) Immunogenic
epitopes in the structure of GAS ADI are highlighted in rainbow colors.
Inactivation of ADI for Use as a GAS Vaccine Candidate
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wild-type and mutant ADIs. This generated high-titer antisera
capable of recognizing native ADI on the surface of GAS. Subse-
quently, we probed an ADI peptide array with serum raised
against wild-type ADI to reveal the linear B cell epitopes. Ten
linear epitopes were identified. Mutation of the D166, H275, and
D277 residues did not affect the pattern of epitopes recognized by
anti-ADI sera. The E220 and C401 residues fell directly adjacent to
or within linear epitopes of ADI. Therefore, mutation of E220 or
C401 in an optimized vaccine preparation is less desirable, as this
may alter the epitopes targeted and subsequently recognized by
host-derived antibodies. In addition, the serum generated against
the H275A mutant ADI had reduced binding to the surface of
whole GAS (when assessed by flow cytometry). For this reason,
mutation of the H275 residue is less advisable for the preparation
of an optimized vaccine preparation.
Analysis of the structure of the mutant ADIs indicated that the
D166A, E220A, H275A, and D277A mutant ADIs had secondary-
structure and oligomerization properties equivalent to those of
wild-type ADI. On the other hand, the mutation of cysteine 401 to
alanine had an unexpected effect. The C401A mutant protein lost
its enzyme activity but also showed some change in secondary
structure compared to that of wild-type ADI and adopted a solely
tetrameric state, with no monomer or dimer detected. Wild-type
ADI did not form any tetramers but rather existed only as a
monomer-dimer mixture. When antiserum raised against the
C401A mutant protein was used to probe the peptide array, only 5
of the 10 immunogenic epitopes detected by anti-wild-type ADI
serum were detected. Presumably, the conformation disruption,
in addition to the change in oligomeric state, altered the epitopes
recognized by the antiserum. We conclude that the C401A muta-
tion would be a less attractive choice for optimization of ADI as a
GAS vaccine candidate.
ADI does not possess a human ortholog. Our previous study
reported that ADI does not react with human heart tissue or hu-
man sera obtained from individuals living in regions with en-
demic disease (10). Prior to further development of ADI as a GAS
vaccine candidate, we wanted to confirm that anti-ADI serum
does not cross-react with host proteins possessing structural sim-
ilarity. The active site of ADI is highly conserved among GAS ADI,
M. arginini ADI, P. aeruginosa ADI, and human PAD4. Given the
level of conservation in the active sites of GAS ADI and human
PAD4, we assessed whether recombinant wild-type ADI could cit-
rullinate known host-derived targets of PAD4, including histone
H3, the chemokine IL-8, and the antimicrobial peptide LL-37.
While recombinant PAD4 citrullinated each of these targets
in vitro, recombinant ADI did not. Thus, it appears that GAS ADI
does not mimic the functionality of PAD4 during infection of the
host. Even though GAS ADI and human PAD4 show some struc-
tural similarities in the active-site region, they do not share signif-
icant amino acid sequence identity or perform the same biological
function. Western blotting and ELISAs indicated that anti-ADI
sera did not recognize human PAD4 in vitro. Therefore, the ad-
ministration of optimized ADI in a GAS vaccine preparation is not
expected to generate antibodies that bind to or interfere with the
function of PAD4 in the host.
ADI has been reported to protect GAS from the low internal
pH of host cells, specifically, to shield streptococcal cells on the
respiratory surfaces or within phagolysosomes (11, 12, 30). Simi-
larly, in Listeria monocytogenes, ADI has been found to promote
extracellular acid tolerance (31). ADI has previously been re-
ported to influence GAS virulence factor expression, including the
expression of the hyaluronic acid capsule and pyrogenic exotoxin
SpeB (32). Through the modulation of the expression of such
virulence factors, ADI is also thought to influence the internaliza-
tion of GAS into epithelial cells (32). GAS ADI is also thought to
play a role in the inhibition of human peripheral blood mononu-
clear cell (PBMC) proliferation (11, 33). By doing so, ADI may
endow GAS with the ability to downregulate or modulate the host
immune response to infection. The inclusion of an optimized mu-
tant ADI in a future GAS vaccine formulation may not only lead to
opsonophagocytosis of GAS, as reported previously (10), but may
also disrupt ADI modulation of host PBMC proliferation and
GAS virulence factor regulation at the site of infection.
We suggest that two of our designed mutant ADIs, the D166A and
D277A mutant proteins, are ideal for inclusion in a GAS vaccine. The
secondary structure and oligomerization state of these mutant pro-
teins remained equivalent to those of the wild-type protein. These
residues do not fall within linear B cell epitopes. Antisera raised
against the D166A and D277A mutant proteins were of high titer,
recognize the same immunogenic epitopes as wild-type ADI, and
detect native ADI associated with the surface of GAS.
FIG 4 Comparison of GAS ADI to human PAD4. (A) Structural alignment of
GAS ADI (pink) with human PAD4 (green). The superposition is centered on
the /-propeller domains, omitting the orthogonal bundle from ADI and the
two N-terminal all- domains from PAD4. ADI active-site residues D166,
E220, H275, D277, and C401 align closely with the corresponding residues in
PAD4. (B) Unlike human PAD4, GAS ADI does not citrullinate host targets,
histone H3, LL-37, or IL-8 in vitro. Host targets were incubated with 5 M ADI
(left lane), 500 nM PAD4 (middle lane), or neither (right lane) for 1 h at 37°C.
The reaction was immediately stopped by incubation with SDS-PAGE loading
buffer for 15 min at 95°C. Samples containing 1.5 g of target protein were
separated by 15% PAGE and either stained with Coomassie blue (top) or
transferred to nitrocellulose membrane for Western blotting with antibodies
for the detection of citrulline (bottom). (C) Anti-ADI serum does not recog-
nize recombinant human PAD4 in a Western blot assay. Samples containing
2 g of ADI (right lane) or PAD4 (left lane) were separated by 15% PAGE and
either stained with Coomassie blue (top) or transferred to nitrocellulose mem-
brane for Western blotting (bottom).
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MATERIALS AND METHODS
Bacterial strains and plasmids used in this study. GAS M1T1 strain 5448
(emm1) has been described elsewhere (34). Escherichia coli strain BL21
Star (DE3) (Invitrogen) was used for protein expression.
Construction of ADI expression vector and site-directed mutagen-
esis. The full-length sagP gene encoding ADI was amplified from GAS
strain 5448 previously (10). The sagP gene was cloned into the pET151
expression vector (Invitrogen) in accordance with the manufacturer’s in-
structions. Individual residues were targeted for site-directed mutagenesis
on the basis of their positions in the GAS ADI structure and following
comparison to ADI structures from M. arginini (19) and P. aeruginosa
(20) in which the active site had been defined. Residues of interest (D166,
E220, H275, D277, and C401) were mutated to alanine by QuikChange XL
site-directed mutagenesis (Stratagene) (for the primers used, see Table S2
in the supplemental material) as previously described (35).
Recombinant protein expression and purification. Expression plas-
mids were transformed into E. coli strain BL21 Star (DE3), and recombi-
nant protein expression was performed as previously described (35). Cells
were frozen at 80°C and lysed with 20 ml of lysis buffer per liter of
original culture (20 mM Tris [pH 7.6], 300 mM NaCl, 3 mM
2-mercaptoethanol [2-ME], 10% [vol/vol] glycerol, 1 mM phenylmeth-
ylsulfonyl fluoride [PMSF], 5 mM imidazole, 1 mg/ml lysozyme, 1 Com-
plete protease inhibitor cocktail [Roche] tablet). Lysate was sonicated for
10 20-s intervals with alternating rest periods of 20 s and placed on a
suspension mixer (Ratek Instruments) for 30 min at 4°C. Lysate was cen-
trifuged at 20,000  g for 1 h at 4°C. Ni-nitrilotriacetic acid (NTA) resin
(Merck Millipore) was added to the cleared lysate, a 2-ml bed volume per
20 ml of lysate, and incubated on a suspension mixer (Ratek Instruments)
for 1 h at 4°C. The mixture was applied to an Econo-Pac chromatography
column (Bio-Rad), and the lysate passed through the resin by gravity flow.
The resin was washed with 20-ml aliquots of wash buffer (20 mM Tris
[pH 7.6], 150 mM NaCl, 3 mM 2-ME, 5% [vol/vol] glycerol, 1 mM PMSF)
each with an increasing concentration of imidazole, 20, 50, and 100 mM,
respectively. Recombinant protein was eluted by using 1-ml fractions of
elution buffer (20 mM Tris [pH 7.6], 150 mM NaCl, 3 mM 2-ME, 5%
[vol/vol] glycerol, 1 mM PMSF, 250 mM imidazole). Fractions containing
protein were pooled and dialyzed at 4°C overnight against 20 mM Tris
(pH 7.6) and 150 mM NaCl. Protein concentration was determined with
the NanoDrop 2000 (Thermo Scientific) and the bicinchoninic acid pro-
tein assay kit (Sigma-Aldrich). The extinction coefficient of ADI,
26,485 M1 cm1, was obtained from the ProtParam tool on the Expasy
website (http://web.expasy.org/protparam/).
Recombinant protein purification and His tag cleavage for crystal-
lography. Expression of wild-type ADI, cell lysis, and Ni-NTA purifica-
tion were performed as described above. Following purification, fractions
containing protein were pooled and tobacco etch virus protease was
added (0.1 mg per liter of starting culture) and the mixture was dialyzed
against a combination of 20 mM Tris (pH 7.6), 150 mM NaCl, 3 mM
2-ME, and 10% glycerol at 4°C overnight. A second Ni-NTA purification
was performed to separate cleaved ADI from uncleaved ADI. Ni-NTA
resin (Merck Millipore), 1-ml bed volume, was added to the dialyzed
sample prior to 1 h of incubation on the suspension mixer (Ratek Instru-
ments) at 4°C. The mixture was applied to an Econo-Pac chromatography
column (Bio-Rad), and the sample passed through by gravity flow. The
resin was washed with 10-ml aliquots of wash buffer (20 mM Tris
[pH 7.6], 150 mM NaCl, 3 mM 2-ME, 10% [vol/vol] glycerol) each with
an increasing concentration of imidazole, 5, 10 20, 50, and 250 mM, re-
spectively. Fractions containing cleaved protein only were concentrated
with an Amicon Ultra-15 centrifugal filter unit with a 10-kDa molecular
mass cutoff (Merck Millipore). Concentrated protein was passed through
a HiLoad 26/60 Superdex 200 gel filtration column (GE Life Sciences)
with s200 buffer (20 mM Tris [pH 7.6], 150 mM NaCl, 5 mM dithiothre-
itol [DTT]). Fractions corresponding to the elution peak were pooled,
concentrated to 6 mg/ml with the aforementioned Amicon filter device,
and snap-frozen in liquid N2.
Crystallization and data collection. Initial searches for crystallization
conditions were performed as 100 nl of well solution plus 100 nl of protein
hanging-drop vapor diffusion experiments with a 75-l reservoir at 18°C,
with sparse-matrix crystallization screens, set up with a TTP Labtech mos-
quito crystal liquid-handling robot. Conditions were further refined as
hanging-drop vapor diffusion experiments with 1 l of well solution added to
1 l of protein equilibrated against a 500-l reservoir at 18°C. Diffracting ADI
crystals formed in 0.1 M bis-Tris (pH 5.5)–20% PEG 3350–0.3 M lithium
sulfate. Crystals were transferred to a 100% Paratone drop before vitrification
in liquid nitrogen. Diffraction experiments were conducted at the Australian
Synchrotron MX1 beam line at 100 K.
Structure determination. Data were integrated and scaled by XDS and
XSCALE, respectively (36). Manual inspection of spot predictions during
integration indicated diffraction from two distinct lattices. These were sepa-
rately integrated and scaled together with a concomitant improvement of
merging statistics. Molecular replacement was performed in PHASER (37)
with ADI from M. arginini as the search model (19). Initial automated re-
building was performed with Phase_and_build from the PHENIX software
suite (38), followed by manual rounds of rebuilding in COOT (39) and re-
finement in phenix.refine (38) or Buster (40). The final model was validated
with Phenix.model_vs_data (41) and Molprobity (42).
SAXS. Purified C401A mutant ADI was dialyzed for 18 h into a mix-
ture of 20 mM Tris (pH 7.6), 150 mM NaCl, and 1 mM DTT. A dilution
series was prepared from this for concentrations between 1.48 and
0.31 mg/ml. SAXS data were collected on a Pilatus 1M detector at the
SAXS/WAXS beam line of the Australian Synchrotron (Melbourne,
Australia). The sample-to-detector distance was 1.6 m, and the wave-
length was 1.12713 Å, yielding a range of momentum transfer of
0.011  q  0.500 Å  1, where q  4  sin()/ and 2 is the scattering
angle. Sample volumes of 50 l were exposed at 298K while flowing
through a 1.5-mm-diameter quartz capillary at a rate of 1 l/s. Images
were taken every 1 s, and data reduction was performed in scatterBrain
(http://www.synchrotron.org.au/index.php/aussyncbeamlines/saxswaxs/
software-saxswaxs). Images were summed, normalized to the transmitted
intensity, averaged, buffer subtracted, and converted to an absolute scale
against the scattering cross-section of water.
The ATSAS 2.5 software package was used for subsequent analyses
(43–45). Guinier analysis was performed for q  Rg  1.3 with
AUTORG, and data sets were examined for concentration dependence
and linearity. P(r) distributions were obtained by indirect transformation
in AUTOGNOM, and molecular weights were estimated from these dis-
tributions with SAXS MoW (46).
The 0.71-mg/ml data set was selected for comparison and modeling
over a range of 0.019  q  0.300 Å  1. Predicted scattering from the
crystallographic tetramer was calculated with CRYSOL (47) by using de-
fault parameters. Rigid-body models were generated with SASREF7 in the
ATSAS Online suite (48) by using four copies of a single monomer from
the crystal structure, P1 symmetry, and no additional restraints.
Colorimetric assay for determination of citrulline. The determination
of citrulline produced from ADI acting on arginine was performed in accor-
dance with the established protocols (49). The amount of citrulline produced
by wild-type ADI was compared to that produced by each mutant ADI by a
one-way analysis of variance (ANOVA) with Dunnett’s post hoc test (P 
0.05).
CD measurements. CD measurements were performed as previously de-
scribed (35).
Nano-ESI-MS. MS was performed on a SYNAPT HDMS mass spectrom-
eter (Waters) with a nano-ESI source. Instrument conditions were as follows:
capillary voltage, 1.5 kV; sample cone, 150 V; extraction cone, 4 V; transfer
collision energy, 8 V. Wild-type and mutant ADIs were buffer exchanged
into 200 mM ammonium acetate (pH 6.8) with a Superdex 200 10/300 G
analytical size exclusion column (GE Healthcare) prior to MS. In all experi-
ments, 2 l of each protein was electrosprayed from gold-coated borosilicate
glass capillaries prepared in house. All spectra were analyzed with MassLynx
V4.1 software with minimal smoothing applied to the raw spectral data.
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Intrinsic tryptophan fluorescence. Tryptophan fluorescence spectra
were acquired with a Cary Eclipse fluorescence spectrophotometer (Varian).
The excitation wavelength was set at 295 nm, and the emission spectra were
recorded from 300 to 450 nm. The slit width for both excitation and emission
spectra was set at 5 nm. Wild-type and mutant ADI were prepared to a final
concentration of 10 M in 25 mM Tris–150 mM NaCl (pH 7.4). Proteins
were incubated at room temperature for 15 min prior to analysis.
Subcutaneous immunization of BALB/c mice and ELISA. Immuniza-
tion of BALB/c mice and subsequent ELISA were performed as previously
described (10). Negative control mice were sham immunized with TBS and
adjuvant only. The experimental protocols described in this report were per-
formed with approval from the University of Queensland Animal Ethics
Committee (approval number SCMB/114/10) and complied with the Aus-
tralian Code of Practice for the Care and Use of Animals for Scientific Pur-
poses (National Health and Medical Research Council, Australia).
Flow cytometry. Flow cytometry was performed as previously described
(10).
Analysis of peptide arrays. An overlapping peptide spot membrane of
ADI was constructed from an acid-stable AC-S01-type amino-pegylated cel-
lulose membrane (AIMS Scientific Products GmbH, Braunschweig, Ger-
many). A series of 15-mer synthetic peptides, each offset by 3 residues, were
assembled at defined intervals on the membrane. The membrane was rehy-
drated with 100% ethanol, washed with TBS for 5 min, and blocked overnight
at 4°C with membrane blocking solution (MBS; 2% skim milk and 0.2%
Tween 20 in TBS). The membrane was washed for 5 min with TBS containing
0.05% Tween 20 (TBST). The membrane was subsequently probed with a
pool of mouse antiserum raised against each ADI protein (or TBS sham se-
rum) diluted 1:100 in MBS for 3 h with gentle rocking at room temperature.
Following three TBST washes, the membrane was incubated with a 1:2,000
dilution of goat anti-mouse IgG-alkaline phosphatase conjugate (Sigma, St.
Louis, MO) for 1.5 h at room temperature. Two TBST washes were per-
formed, followed by two 5-min washes with citrate-buffered saline (NaCl at
8 g/liter, KCl at 0.2 g/liter, citric acid at 10.51 g/liter, pH 7.0). The membranes
were developed with color-developing solution [50 l of 1 M magnesium
chloride per 10 ml, 40 l of 5-bromo-4-chloro-3-indolylphosphate
p-toluidine salt per 10 ml, and 60 l of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide per 10 ml] for 10 min, and the reaction was
terminated by washing with phosphate-buffered saline. The developed mem-
brane array was scanned with a GS-800 calibrated densitometer (Bio-Rad
Laboratories, Hercules, CA). Following reaction of the first antiserum, the
membrane was stripped. In short, the membrane was washed twice with wa-
ter (5 min) and incubated in an excess of dimethylformamide (DMF) until
the blue color of spot signals dissolved. All washing steps were performed for
5 min. The DMF step was repeated, followed by three water washes. Mem-
branes were then washed three times with stripping mixture A (8 M urea, 1%
SDS, 0.5% 2-ME, pH 7.0) in a sonication bath at 40°C, followed by washing
three times with stripping mixture B (10% acetic acid, 50% ethanol). Finally,
the membrane was subjected to three washes with 100% ethanol, followed by
one wash with TBS. Only the more intensely labeled peptide spots were con-
sidered reactive.
Reaction of ADI and PAD4 with host targets. The citrullination assay for
ADI and PAD4 was performed as previously described (50). PAD4 (Cayman
Chemicals), recombinant histone H3 (Cayman Chemicals), IL-8 (Merck
Millipore), and LL-37 (AnaSpec) were all purchased commercially.
Western blot analysis. Western blotting was performed as previously
described (51). Citrulline residues in target proteins were detected with
the Anti-Citrulline (Modified) Detection Kit (Merck Millipore).
Protein structure accession number. The coordinates and structural
factors described in this report have been deposited in the Protein Data
Bank and assigned accession number 4BOF.
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